Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.

Abstract

BACKGROUND:

Somatostatin analogues (SSA) represent one of the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumours (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).

AIM:

To evaluate the efficacy of the long-acting SSA octreotide in MEN1 patients with early-stage duodeno-pancreatic NETs.

PATIENTS AND METHODS:

Forty patients with MEN1 were retrospectively evaluated. Twenty patients with evidence of one or more MEN1-related duodeno-pancreatic NETs < 20 mm in size (age range 26-61 years) were treated with octreotide long-acting octreotide (LAR) as first-line therapy. Treatment duration ranged 12-75 months. At the baseline radiological evaluation, multiple duodeno-pancreatic NETs (range 1-8, size 3-18 mm) were detected.

RESULTS:

An objective tumour response was observed in 10%, stable disease in 80% and progression of disease in 10% of cases. In six patients with abnormally increased CgA, gastrin and/or insulin serum concentrations, a significant clinical and hormonal response occurred in 100% of cases and was stable along the time.

CONCLUSIONS:

Therapy with SSA is highly safe and effective in patients with early-stage MEN1 duodeno-pancreatic NETs, resulting in long-time suppression of tumour and hormonal activity and 10% objective response. This suggests to early start therapy with SSA in patients with MEN1-related NETs.

• Authors: V Ramundo, M Del Prete, V Marotta, F Marciello, L Camera, V Napolitano, L De Luca, L Circelli, V Colantuoni, A Di Sarno, A C Carratù, C de Luca di Roseto, A Colao, A Faggiano, Multidisciplinary Group for Neuroendocrine Tumors of Naples
• Journal: Clinical endocrinology (Clin Endocrinol (Oxf)) Vol. 80 Issue 6 Pg. 850-5 (Jun 2014) ISSN: 1365-2265 [Electronic] England
• PMID: 24443791 (Publication Type: Journal Article)
• Copyright: © 2014 John Wiley & Sons Ltd.

Chemical References

• Gastrins
• Insulin
• Somatostatin
• Octreotide

Topics

• Adult
• Cell Differentiation
• Disease Progression
• Endocrine System (physiology)
• Female
• Gastrins (blood)
• Humans
• Insulin (blood)
• Male
• Middle Aged
• Multiple Endocrine Neoplasia Type 1 (complications, drug therapy)
• Neuroendocrine Tumors (complications, drug therapy)
• Octreotide (therapeutic use)
• Retrospective Studies
• Somatostatin (chemistry)
• Time Factors
• Treatment Outcome